

1 **TITLE PAGE**

2
3 **Title:** Sepsis Subphenotyping Based on Organ Dysfunction Trajectory

4
5 **Authors:**

6 Zhenxing Xu, PhD¹
7 Chengsheng Mao, PhD²
8 Chang Su, PhD³
9 Hao Zhang, PhD¹
10 Ilias Siempos, MD^{4,5}
11 Lisa K Torres, MD^{4,5}
12 Di Pan, DO^{4,5}
13 Yuan Luo, PhD²
14 Edward J Schenck, MD^{4,5}
15 Fei Wang, PhD¹
16

17 **Affiliations:**

18 ¹Division of Health Informatics, Department of Population Health Sciences, Weill
19 Cornell Medicine, New York, NY, USA;
20 ²Division of Health and Biomedical Informatics, Department of Preventive Medicine
21 Center for Health Information Partnerships, Feinberg School of Medicine,
22 Northwestern University, Chicago, IL, USA;
23 ³Department of Health Service Administration and Policy, College of Public Health,
24 Temple University, Philadelphia, PA, USA;
25 ⁴Division of Pulmonary and Critical Care Medicine, New York-Presbyterian
26 Hospital/Weill Cornell Medical Center, New York, NY, USA;
27 ⁵Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA.
28

29 **Corresponding Authors Information:**

30 Fei Wang: 425 E. 61st Street, 3rd Floor, Suite 301, New York, NY.
31 few2001@med.cornell.edu;
32 Edward J Schenck: 425 E. 61st Street, 4th Floor, Suite 402, New York, NY.
33 ejs9005@med.cornell.edu;
34 Yuan Luo: Rubloff Building 11th Floor, 750 N Lake Shore, Chicago Illinois.
35 yuan.luo@northwestern.edu.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

51 **ABSTRACT**

52

53 **Background:** Sepsis is a heterogeneous syndrome, and the identification of clinical
54 subphenotypes is essential. Although organ dysfunction is a defining element of sepsis,
55 subphenotypes of differential trajectory are not well studied. We sought to identify distinct
56 Sequential Organ Failure Assessment (SOFA) score trajectory-based subphenotypes in
57 sepsis.

58

59 **Methods:** We created 72-hour SOFA score trajectories in patients with sepsis from four
60 diverse intensive care unit (ICU) cohorts. We then used Dynamic Time Warping (DTW) to
61 compute heterogeneous SOFA trajectory similarities and hierarchical agglomerative
62 clustering (HAC) to identify trajectory-based subphenotypes. Patient characteristics were
63 compared between subphenotypes and a random forest model was developed to predict
64 subphenotype membership at 6 and 24 hours after being admitted to the ICU. The model was
65 tested on three validation cohorts. Sensitivity analyses were performed with alternative
66 clustering methodologies.

67

68 **Results:** A total of 4678, 3665, 12282, and 4804 unique sepsis patients were included in
69 development and three validation cohorts, respectively. Four subphenotypes were identified
70 in the development cohort: Rapidly Worsening (n=612, 13.1%), Delayed Worsening (n=960,
71 20.5%), Rapidly Improving (n=1932, 41.3%) and Delayed Improving (n=1174, 25.1%).
72 Baseline characteristics, including the pattern of organ dysfunction varied between
73 subphenotypes. Rapidly Worsening was defined by a higher comorbidity burden, acidosis,
74 and visceral organ dysfunction. Rapidly Improving was defined by vasopressor use without
75 acidosis. Outcomes differed across the subphenotypes, Rapidly Worsening had the highest in-
76 hospital mortality (28.3%, p-value<0.001), despite a lower SOFA (mean: 4.5) at ICU
77 admission compared to Rapidly Improving (mortality:5.5%, mean SOFA: 5.5). An overall
78 prediction accuracy of 0.78 (95% CI, [0.77, 0.8]) was obtained at 6 hours after ICU
79 admission, which increased to 0.87 (95% CI, [0.86, 0.88]) at 24 hours. Similar subphenotypes
80 were replicated in three validation cohorts. The majority of patients with sepsis have an
81 improving phenotype with a lower mortality risk, however they make up over 20% of all
82 deaths due to their larger numbers.

83

84 **Conclusions:** Four novel, clinically-defined, trajectory-based sepsis subphenotypes were
85 identified and validated. Identifying trajectory-based subphenotypes has immediate
86 implications for the powering and predictive enrichment of clinical trials. Understanding the
87 pathophysiology of these differential trajectories may reveal unanticipated therapeutic targets
88 and identify more precise populations and endpoints for clinical trials.

89

90 **Keywords:** sepsis, subphenotype, Sequential Organ Failure Assessment (SOFA) score,
91 precision medicine, dynamic time warping

92

93

94

95

96

97

98

99

100

101 **Introduction**

102 Sepsis is defined as a dysregulated immunological response to infection that results in acute
103 organ dysfunction.^{1,2} The morbidity and mortality of sepsis remain high despite decades of
104 research and numerous failed clinical trials.^{3,4} Recent research has highlighted that sepsis is a
105 complex and heterogeneous syndrome, which includes a multidimensional array of clinical
106 and biological features.⁵ Identifying rigorous sepsis subphenotypes that present with similar
107 prognostic markers and pathophysiologic features has the potential to improve therapy.⁶⁻⁹

108

109 Recent sepsis subphenotyping studies used static measurements available soon after
110 admission to the emergency department or intensive care unit (ICU) to characterize
111 patients.^{5,10-12} However, due to the stochastic nature of infection and variable presentation to
112 health care after developing symptoms, static assessments of sepsis subphenotypes may be
113 incomplete, ignoring the dynamic nature of organ failure in sepsis.¹³

114

115 More recently, subphenotypes characterized by dynamic patient temperature trajectories have
116 been identified in sepsis. The differential pattern of temperature change may represent a
117 varied underlying inflammatory response to infection.¹ The trajectory of the Sequential
118 Organ Failure Assessment (SOFA) score after ICU admission have been used to predict
119 outcomes and improve prognostic stratification in sepsis.^{13,14} In a recent study, Sanchez-Pinto
120 et al.¹⁵ leveraged a matrix factorization based approach to identify multiple organ dysfunction
121 syndrome subphenotypes according to longitudinal pediatric SOFA (pSOFA) scores, but their
122 approach was focusing on the subphenotypes captured by the “motifs”, or frequent
123 subsequence patterns, of the SOFA trajectories, which may not characterize the long term
124 trends encoded in those trajectories well. However, whether the trajectory of multisystem
125 organ failure is associated with distinct phenotypic patterns in sepsis remains largely
126 unexplored. Identifying distinct subphenotypes of organ dysfunction trajectory in sepsis can
127 refine our understanding of the natural history of sepsis in the ICU in response to standard of
128 care treatment and define patterns of disease that may benefit from novel therapeutic
129 strategies.¹⁶

130

131 The objective of this study was to develop and evaluate sepsis subphenotypes. The first goal
132 was to determine whether distinct SOFA score trajectory-based subphenotypes in patients
133 with sepsis can be identified through the electronic health record. The second goal was to
134 understand whether those different subphenotypes are associated with the patterns of
135 biomarkers and clinical outcomes. The third goal was to determine whether the identified
136 subphenotypes can be predicted by using patient baseline characteristics and early-stage
137 clinical features.

138

139 **Methods**

140 **Overview**

141 We did a cohort study on datasets that contained granular patient level data from a total of
142 221 hospitals in the United States, whose overall workflow is illustrated in Figure 1. Our goal
143 was to derive sepsis subphenotypes of patients in ICU according to their SOFA organ
144 dysfunction trajectories using dynamic time warping (DTW)¹⁷ and hierarchical agglomerative
145 clustering (HAC)¹⁸. We then characterized these subphenotypes using comprehensive patient
146 information including demographics, comorbidities, use of mechanical ventilation, type of
147 ICU unit, admission source, organ source of sepsis, and examined their associated clinical
148 outcomes as well as clinical biomarkers. We further built multiple random forest models to
149 predict the derived subphenotypes from different time points’ patient clinical characteristics.
150 To ensure replicability, the same analysis pipeline was conducted in three validation cohorts.

151

152 **Definition of sepsis and study population**

153 The development cohort (Medical Information Mart for Intensive Care III database: MIMIC-
154 III) was from Beth Israel Deaconess Medical Center (BIDMC) with admissions dating from
155 2001-2012. which has 673 licensed beds, including 493 medical/surgical beds, 77 critical
156 care beds, and 62 OB/GYN beds.¹⁹ The first validation cohort was from Northwestern
157 Medicine Enterprise Data Warehouse (NMEDW) , which is a network of eleven hospitals
158 located in northern Illinois with 2,554 beds in total, with ICU admissions dating from 2012-
159 2019.²⁰ The second validation cohort was from the eICU collaborative research database,
160 which combined multi-center data from patients who were admitted to one of 335 units at
161 208 hospitals located throughout the US between 2014 and 2015.²¹ The third validation
162 cohort was from Weill Cornell Critical care Database for Advanced Research (CEDAR) with
163 ICU admissions dating from 2001-2020, which was built on NewYork-Presbyterian/Weill
164 Cornell Medical Center (NYP/WCMC), including 862 beds in total.²² The inclusion-
165 exclusion cascade for the patients are shown in Supplemental Figure S1, where Sepsis-3
166 criteria are defined as in Singer et al.²

167

168 **SOFA score computation and model descriptions**

169 The SOFA score was derived from six organ-specific subscores including respiration,
170 coagulation, liver, cardiovascular, CNS, renal¹⁶, which was obtained every 6 hours within the
171 first 72 hours of ICU admission. For each 6-hour period, the worst variable value was used to
172 compute the SOFA subscores. To obtain the urine output during 6 hours, we divided daily
173 urine output by 4. The lowest GCS for each 6 hour period was used irrespective of sedation.
174 Missing values (Supplemental Table S14) were imputed using last observation carried
175 forward (LOCF) and next observation carried backward (NOCB).²³ If there was no any value
176 during the first 72 hours, we used 0 to fill.

177

178 After the SOFA scores were derived, each patient is represented as a vector of 12 SOFA
179 scores from the first 6 hours to the last 6 hours across the 72 hours period after ICU
180 admission. Then, DTW and HAC were used to derive subphenotypes.¹⁷ In particular, DTW
181 was used to evaluate the similarities between pairwise patient SOFA trajectories
182 (Supplemental Figure S19 and S20). This method can capture the differences among the
183 evolution heterogeneity in terms of the temporal curves, which can assess similarity between
184 patients robustly. HAC was then used to perform clustering among patients based on the
185 similarities obtained from DTW. Multiple clustering indices (Supplemental Appendix 7)
186 were calculated to determine the optimal numbers of subphenotypes.

187

188 **Subphenotype reproducibility and prediction**

189 To ensure the robustness of the derived subphenotypes, we re-derived them with group-based
190 trajectory modeling (GBTM), which is one type of latent class analysis (LCA) that assigns
191 each patient a probability of belonging to each particular subphenotype on the basis of
192 maximum likelihood estimation.²⁴

193

194 We trained a random forest model to predict the derived subphenotypes from the baseline
195 patient clinical collected characteristics at successive time points after ICU admission, with
196 the goal of examining whether the trajectory subphenotypes could be predicted early.
197 Candidate predictors included demographics, comorbidities, SOFA subscores, lab tests, and
198 vital signs. Predictor contributions were evaluated with the Shapley additive explanations
199 (SHAP) strategy.²⁵

200

201 **Statistical Analysis**

202 Data were analyzed using tslearn package 0.3.1 and scikit-learn package 0.22.2 with Python
203 3.7. Survival analysis to 28 days was performed using Kaplan-Meier curves. Statistical
204 significance was set at $p < 0.05$, and all tests were 2-tailed. The detailed descriptions about
205 statistical testing are shown in Supplemental Appendix 2.

207 **Results**

208 **Cohort characteristics**

209 Our development cohort MIMIC-III had 4,678 sepsis patients with the median age 65.9 years
210 (Interquartile Range (IQR) [53.7-77.9]), which included 2,625 male (56.1%) and 3,367 white
211 (71.9%) patients. The overall in-hospital mortality rate was 10.9%, and the median ICU
212 length-of-stay was 2.8 days (IQR [1.6-5.6]). There were 1,893 patients (40.5%) treated with
213 mechanical ventilation during the first three days. The mean baseline SOFA score obtained
214 from the first 6 hours after ICU admission was 4.96 (Standard Deviation (SD): 2.8). Most of
215 the patients (2,611, 55.8%) were in the medical intensive care unit (MICU). The overall
216 demographic distributions of the validation cohorts from NMEDW (n=3,665) and eICU²¹
217 (n=12,282) are similar to the development cohort. Patients in validation cohort CEDAR
218 (n=4,804) were older (median age 77 years (IQR [66.0-88.0]) compared to development
219 cohort. The overall in-hospital mortality rates of patients in NMEDW, eICU, and CEDAR
220 were 14.0%, 10.5%, and 19.9%, respectively. The median length-of-stay were 3.8 days (IQR
221 [1.9-7.9]), 2.8 days (IQR [1.7-5.1]), 4.4 days (IQR [2.7-7.9]). There were 1,524 (41.6%),
222 5,772 (47.0%) and 2,263 (47.1%) patients that needed mechanical ventilation in the first three
223 days. The mean baseline SOFA scores were 5.68 (SD:2.8), 5.9 (SD:3.1), and 6.4 (SD:3.1) in
224 validation cohorts.

226 **Comparisons between Survivors and Nonsurvivors**

227 In the development cohort, nonsurvivors were older than survivors, with a median age of 71.5
228 years (IQR, [59.9-80.9]) compared with 65.2 years for survivors (IQR, [53.2-77.4], p-value <
229 0.001). Nonsurvivors had higher comorbidity burden with a median Elixhauser index score²⁶
230 7.0 (IQR [2.0-12.0]). Median ICU length-of-stay for nonsurvivors was 3.95 days (IQR [1.9-
231 7.7]), and the rate of mechanical ventilation during the first three days was 59.8%.
232 Nonsurvivors had higher baseline SOFA scores, with a mean value 7.1 (SD: 3.7). More
233 nonsurvivors were admitted in MICU (Supplemental Table S1). Similar statistics in
234 validation cohorts are shown in Supplemental Tables S2, S3, and S4.

236 **SOFA trajectory and the derived subphenotypes**

237 Based on the pairwise patients' SOFA trajectory similarity matrix obtained from DTW, we
238 generated clustermaps with HAC (Supplemental Figure S2), where four distinct clusters were
239 identified as subphenotypes. The number of clusters was determined according to multiple
240 clustering indexes (Supplemental Appendix 6 and Table S5).

242 The overall trajectory and prevalence of each subphenotype across four cohorts are shown in
243 Figure 2 and 3. Specifically, in the development cohort, the Rapidly Worsening
244 subphenotype (n=612, 13.1%) was characterized by continuously increased SOFA scores
245 from a mean (SD) of 4.5 (2.8) at admission to more than 7 at 72 hours. This subphenotype
246 had the fewest patients. The Delayed Worsening subphenotype (n=960, 20.5%) was
247 characterized by decreased SOFA scores within the first 48 hours from a mean (SD) of 5.2
248 (2.7) at baseline to 3.7 (2.8), followed by an increase over the last 24 hours. The Rapidly
249 Improving subphenotype (n=1,932, 41.3%) was characterized by a consistent continuous
250 improvement in SOFA scores from a mean (SD) of 5.54 (2.9) at baseline to less than 3. This

251 was the most common subphenotype and it had the highest SOFA score at baseline. The
252 Delayed Improving subphenotype (n=1,174, 25.1%) was characterized by an increase and
253 then a gradual decrease in SOFA score over 72 hours. It had the lowest SOFA score at
254 baseline with mean (SD) 4.0 (2.4). Similar trajectory trends were obtained in all three
255 validation cohorts (Figure 2 and 3, Supplemental Appendix 3). Individual SOFA subscore
256 trajectories for each subphenotype are provided in Supplemental Figures S3, S4, S10, and
257 S14.

258

259 **Patient characteristics comparisons across subphenotypes**

260 Patient characteristics differed across subphenotypes (Table 1, Figure 4, Figure 5, and
261 Supplemental Table S6). Specifically, Rapidly Worsening patients had the highest rates of
262 mechanical ventilation (46.41%), the highest median Elixhauser comorbidity burden value of
263 5 (IQR [0-10]) but the lowest baseline SOFA score compared to the other subphenotypes.
264 They had the highest mortality rate (Figure 4(A) 28.3%, p-value<0.001) and a longer length
265 of stay (Table 1, 2.9 days, p-value<0.001). Rapidly Improving patients had the lowest rate of
266 mortality (Figure 4(A) 5.5%) and mechanical ventilation (37.9%), and the shortest length-of-
267 stay (2.4 days). It had the highest proportion of patients meeting criteria for septic shock
268 (15.5%, p-value=0.002). Delayed Improving and Delayed Worsening patients had lower rates
269 of mortality (10.7%, 10.6%) and mechanical ventilation (42.5%, 39.3%) than the Rapidly
270 Worsening subphenotype. The median age of the four subphenotypes were similar in the
271 development cohort. Male patients were more common in all subphenotypes. Chord diagrams
272 (Figure 5) showed the differences of subphenotypes in terms of abnormal clinical biomarkers.
273 The Rapidly Worsening group was more likely to have patients with abnormal cardiovascular
274 biomarkers (bicarbonate, troponin T or I, lactate) and hematologic (such as hemoglobin, INR,
275 platelet, glucose, RDW). Patients in this subphenotype had a higher chronic comorbidity
276 burden and had abnormal SOFA subscores including respiration, coagulation and liver. The
277 Rapidly Improving patients were more likely to have abnormal inflammatory lab values
278 (temperature, WBC, bands, CRP, albumin, lymphocyte percent) and abnormal
279 cardiovascular, CNS and renal SOFA subscores. There was a lower chronic comorbidity
280 burden in this subphenotype. Delayed Worsening group had more abnormal hematologic and
281 respiration, coagulation, CNS, and SOFA renal subscores. Abnormal respiration, coagulation,
282 cardiovascular SOFA subscores were strongly associated with Delayed Improving. The
283 characteristics on validation cohorts are provided in Supplemental Appendix 4 and Tables S7,
284 S8, S9, S10, S11, and S12. The associations between all comorbidities and subphenotypes
285 were investigated and shown in Supplemental Tables S16, S17, S18, and S19. Multiple
286 comorbidities such as congestive heart failure, renal failure, liver disease, cancer showed the
287 differences among subphenotypes.

288

289 **Subphenotype reproducibility and prediction**

290 Sensitivity analysis with another clustering approach GBTM confirmed the four
291 subphenotypes with the data from development cohort (Supplemental Figure S8). Patients'
292 memberships of the four subphenotypes re-derived by GBTM were highly consistent with
293 those obtained from HAC (Supplemental Figure S9), and thus we did not find substantial
294 changes in clinical characteristics of those subphenotypes derived from the sensitivity
295 analysis (Supplemental Table S13).

296

297 We trained random forest models for predicting subphenotypes according to early-stage
298 patient characteristics. Overall, with the first 6 hours after ICU admission, the models
299 obtained the accuracy of 0.78 (95% Confidence Interval [CI] [0.77, 0.8]) in development
300 cohort and 0.79 (95% CI [0.78, 0.8]), 0.81 (95% CI [0.8, 0.84]), and 0.82 (95% CI [0.81,

0.84]) in NMEDW, eICU, and CEDAR validation cohorts respectively. Predictor contributions on four cohorts are shown in Figure 6 and Supplemental Figures S5, S11, and S15, which demonstrated different patterns when predicting different subphenotypes. For example, creatinine, bicarbonate, RDW, and BUN contributes more for predicting the Rapidly Improving group, while platelet, INR, AST and lactate contributed more to the prediction of the Rapidly Worsening group. The prediction performance at successive time points are shown in Supplemental Figure S18. The accuracy increased to 0.87 (95% CI [0.86, 0.88]) in development cohort and 0.86 (95% CI [0.85, 0.88]), 0.86 (95% CI [0.85, 0.87]), and 0.84 (95% CI [0.83, 0.85]) in NMEDW, eICU, and CEDAR validation cohorts at the 24 hours after ICU admission, respectively.

Table 1. Patient Characteristics among Subphenotypes in the Development Cohort

Characteristics	Total (N=4,678)	DI (N=1,174)	RI (N=1,932)	DW (N=960)	RW (N=612)	P- value [†]
Age, median (IQR)	65.9 [53.7-77.9]	67.25 [54.8-79.2]	65.3 [53.3-77.2]	66.9 [53.9-78.3]	64.5 [52.5-76.7]	0.204
Sex, No. (%)						
Male	2625 (56.1)	594 (50.6)	1100 (56.9)	548 (57.1)	383 (62.6)	0.081
Female	2053 (43.9)	580 (49.4)	832 (43.1)	412 (42.9)	229 (37.4)	
Race, No. (%)						0.207
WHITE	3367 (71.9)	870 (74.1)	1398 (72.4)	670 (69.8)	429 (70.1)	
BLACK	424 (9.1)	92 (7.8)	189 (9.8)	101(10.5)	42 (6.9)	
OTHER	887 (18.9)	212 (18.1)	345 (17.9)	189 (19.7)	141(23.0)	
Elixhauser index, median (IQR)	4.0 [0.0-9.0]	4.0 [0.0-9.0]	4.0 [0.0-9.0]	4.0 [0.0-9.0]	5.0 [0.0-10.0]	0.015
Length stay, median (IQR)	2.8 [1.6-5.6]	2.9 [1.8-6.2]	2.4 [1.5-4.8]	2.9 [1.7-5.3]	2.9 [1.6-6.7]	< 0.001
Mechanical ventilation at admission, No. (%)	1893 (40.5)	499 (42.5)	733 (37.9)	377 (39.3)	284 (46.4)	< 0.001
Baseline SOFA, mean (SD)	4.96 (2.8)	4.0 (2.4)	5.5 (2.9)	5.2 (2.7)	4.5 (2.8)	< 0.001
ICU unit at admission, No. (%)						0.037
SICU	771 (16.5)	185 (15.8)	341 (17.7)	135 (14.1)	110 (17.9)	
CCU	443 (9.5)	117 (9.9)	167 (8.6)	94 (9.8)	65 (10.6)	
TSICU	593 (12.7)	173 (14.7)	226 (11.7)	119 (12.4)	75 (12.3)	
MICU	2611 (55.8)	634 (54.0)	1087 (56.3)	569 (59.3)	321 (52.5)	
CSRU	260 (5.6)	65 (5.5)	111 (5.8)	43 (4.5)	41 (6.7)	
Admission location, No. (%)						0.196
Transfer from other hospital	810 (17.3)	213 (18.1)	304 (15.7)	165 (17.2)	128 (20.9)	
Emergency room	1497 (32.0)	355 (30.2)	628 (32.5)	328 (34.2)	186 (30.4)	
Clinic referral	1985 (42.4)	493 (41.9)	847 (43.8)	396 (41.3)	249 (40.7)	
Transfer from ward	4 (0.1)	2 (0.2)	1 (0.1)	1 (0.1)	0 (0.0)	
Physician referral	367 (7.9)	106 (9.0)	145 (7.5)	69 (7.2)	47 (7.7)	
Transfer from skilled nursing facility	15 (0.3)	5 (0.4)	7 (0.4)	1 (0.1)	2 (0.3)	
Infection item, No. (%)						
Central nervous system	56 (1.2)	10 (0.9)	27 (1.4)	8 (0.8)	11 (1.8)	0.189
Intra-abdominal	880 (18.8)	230 (19.6)	363 (18.8)	172 (17.9)	115 (18.8)	0.808
Pneumonia	1257 (26.9)	328 (27.9)	494 (25.6)	262 (27.3)	173 (28.3)	0.385
Septicemia bacteremia	1587 (33.9)	359 (30.6)	717 (37.1)	300 (31.3)	211 (34.5)	< 0.001

Skin soft tissue	276 (5.9)	60 (5.1)	140 (7.3)	42 (4.4)	34 (5.6)	0.008
Urinary tract	1044 (22.3)	276 (23.5)	439 (22.7)	228 (23.8)	101 (16.5)	0.003
Septic shock, No. (%)	635 (13.6)	148 (12.6)	299 (15.5)	101 (10.5)	87 (14.2)	0.002

313 Definition of abbreviations: IQR--interquartile range; SD--standard deviation; SOFA--Sequential Organ Failure
314 Assessment; SICU-- Surgical ICU; CCU-- Coronary Care Unit; TSICU--Thoracic Surgery ICU; MICU--
315 Medical ICU; CSRU--Cardiac Surgery ICU. †p-value calculated by Chi-square test/Fisher's exact test, or
316 student's t-test/Mann-Whitney test where appropriate. DI: Delayed Improving. RI: Rapidly Improving. DW:
317 Delayed Worsening. RW: Rapidly Worsening. Infection items were defined based on ICD-9 code (see
318 Supplemental Table S15).

319

320 Discussion

321 We reported four sepsis subphenotypes based on dynamic organ dysfunction trajectories
322 using a data-driven methodology. DTW was used to calculate patients' SOFA trajectory
323 similarities because of its capability of capturing heterogeneous evolution among the
324 temporal sequences robustly, based on which HAC was leveraged to identify patient groups
325 with similar trajectories. The subphenotypes identified were Rapidly Worsening, Delayed
326 Worsening, Rapidly Improving, and Delayed Improving. Patients in the Rapidly Worsening
327 subphenotype had progressive organ dysfunction with the ongoing ICU stay. The two
328 Delayed groups had unstable organ dysfunction over the study period and the Rapidly
329 Improving group had the highest admission organ dysfunction but quickly improved.
330 Outcomes followed SOFA trajectory across each subphenotype were irrespective of
331 traditional baseline SOFA score and septic shock categories.

332

333 A major strength of this analysis is that we have identified time-dependent progression
334 patterns that may be related to the differential response of specific organ dysfunction to
335 standard of care interventions. For example, the Rapidly Improving group had cardiovascular
336 and respiratory failure at admission that resolved over 72 hours. The Rapidly Worsening
337 groups developed multisystem organ failure including visceral organ dysfunction, specifically
338 liver failure in addition to cardiovascular and respiratory failure. These differential patterns
339 suggest varying time-dependent, treatment responsive organ dysfunction pathophysiology in
340 sepsis. The cardiovascular and respiratory subscores are driven by the vasopressor dose and
341 PaO₂/FiO₂ respectively, which may respond to therapeutic interventions such as
342 corticosteroids, volume resuscitation, and the application of PEEP or therapeutic suctioning.²⁷
343 However, as demonstrated by our analysis, sepsis-related renal and liver failure may be less
344 modifiable with our current therapeutic strategies over the past twenty years.^{28,29} Our study
345 highlights that patterns of organ dysfunction in patients with sepsis are Rapidly Improving,
346 Rapidly Worsening and Delayed. Each of these patterns may be due to a different
347 pathophysiology and benefit from different treatments in the future. However, these findings
348 have immediate implications for those designing clinical trial endpoints such as change in
349 SOFA subscore.³⁰ Moreover, enrolling patients with a Rapidly Improving phenotype into a
350 trial evaluating a therapeutic agent to reduce the duration of organ dysfunction will unlikely
351 reveal a difference.

352

353 It deserves noting that our Rapidly Improving patients had better outcomes across all patients
354 studied, but still represented 21%, 36%, 21%, and 24% of all deaths in our development and
355 validation cohorts (NMEDW, eICU, and CEDAR cohorts) respectively, despite an overall
356 5%, 10%, 5%, and 9% in-hospital mortality. This low mortality rate but high numbers of
357 absolute deaths highlights that further research is needed to understand the cause of death in
358 patients with rapidly improving organ dysfunction in sepsis.³¹ The Rapidly Worsening
359 subphenotype was less common compared to rapidly improving and may represent patients
360 with our classical understanding of septic shock.³² More recent evidence suggests that the

361 pathophysiology of early, progressive organ dysfunction in our Rapidly Worsening patients
362 may be due to over exuberant activation of necroinflammatory cell death pathways in
363 multiple organs, highlighting the need for novel treatment strategies.³³⁻³⁵ The Delayed
364 Worsening and Improving subphenotypes, had intermediate outcomes across our cohorts, and
365 more nuanced differences in clinical characteristics. These trajectories may be influenced by
366 non-resolving inflammation or immune paralysis.^{36,37} Further understanding of the biology
367 underlying these subphenotypes will be critical to develop the next generation of treatments
368 for sepsis in all its forms.

369
370 The potential for distinct pathophysiologic etiologies for the differential trajectories is
371 supported by the differential patterns of organ dysfunction, infectious source, vital signs,
372 inflammatory, hematologic, and cardiovascular variables at admission to the ICU. As shown
373 in Figure 5, and Supplemental Figures S6, S7, S12, S13, S16, and S17, there were different
374 variables associated with different groups over the course of the study. For example, those
375 patients of Rapidly Improving were more likely to have more abnormal inflammatory
376 markers (such as WBC, bands, albumin, temperature, lymphocyte) and more abnormal values
377 on cardiovascular, and CNS subscores. They were also more likely to have urosepsis. There
378 was a lower comorbidity score in patients with this subphenotype, which suggests that sepsis
379 outcomes may be more dependent on underlying illness. The Rapidly Worsening patients had
380 more comorbidities and distinct derangements in clinical variables associated with metabolic
381 acidosis and hypoperfusion, e.g. a low bicarbonate and higher lactate, and disseminated
382 intravascular coagulation, e.g. low platelets and a higher INR and respiratory failure. Both of
383 the Delayed subphenotypes had less specific variables associated with group membership,
384 including inflammatory, hepatic, hematologic and pulmonary associated with Delayed
385 Improvement and hematologic, cardiovascular and renal variables associated with Delayed
386 Worsening. These differences may be related to secular trends in therapeutics and differing
387 case mixes in each cohort.

388
389 We built multivariable prediction models for the identified trajectory subphenotypes from
390 patient baseline characteristics and early-stage clinical features. Several interesting findings
391 were obtained. (1) A high comorbidity score tended to predict the subphenotypes of Rapidly
392 Worsening because patients with high comorbidity burden were more likely to present worse
393 organ dysfunction in ICU; (2) The roles of lab tests and vital signs were different on
394 prediction. For example, low Platelets had a positive impact on the Rapidly Worsening
395 prediction and high Platelets had a positive impact on the Rapidly Improving prediction.
396 These prediction models may enhance the clinical utility of the identified subphenotypes in
397 practice, as they can be predicted with the EHR information captured within the early hours
398 of ICU admission, especially for Rapid Improving and Rapid Worsening subphenotypes,
399 which has important clinical implications as discussed above. Our model can be implemented
400 within the EHR system as a risk calculator for subphenotype assignments.

401
402 Our manuscript complements and adds to other recent study of sepsis subphenotypes. For
403 example, Seymour et al. and Knox et al. each identified four subphenotypes that were
404 associated with organ dysfunction patterns and clinical outcomes in patients with sepsis using
405 a panel of baseline clinical variables.^{5,10} There is some overlap in our high risk groups,
406 notably both include liver injury and shock. However, our work demonstrates that the
407 difference in outcome in this group is due to progressive non-resolving organ dysfunction
408 that calls for novel treatments. Prior work by Ferreira et al and Sakr et al used changes in the
409 SOFA score after ICU admission to improve prognostic stratification in sepsis, but did not

410 use these changes to establish subphenotypes. Bhavani et al. used longitudinal temperature
411 trajectories to identify four sepsis subphenotypes, with significant variability in inflammatory
412 markers and outcomes, highlighting the potential for novel immune signatures to be
413 uncovered through trajectory analysis.¹ Differential organ dysfunction trajectory may be
414 related to the immune response but may also be explained by differences in preexisting
415 frailty, effective source control, resuscitation and processes of care.

416
417 This study has several limitations. First, our sepsis subphenotypes were identified based on
418 the data-driven method, which may not be directly related to underlying differences in
419 biology. Integration of biological data may help refine our understanding of differential
420 disease progression and the potential for therapeutics to alter the course. Second, although we
421 used many separate hospitals in validation, all of them are located in the United States, which
422 may limit generalizability to other locations of care. Moreover, these observational cohorts
423 may not directly reflect sepsis clinical trial populations but are representative of academic
424 and community hospitals across the United States. Third, we did not evaluate the effect of
425 specific randomized interventions on SOFA score trajectory. Fourth, this identified sepsis
426 subphenotypes only focused on patients admitted to an ICU, which is subject to differences in
427 ICU admission practices across institutions. Last but not the least, we did not investigate the
428 association between care processes and the subphenotypes, which would be an important
429 topic in future research.

430

431 **Conclusion**

432 We discovered four sepsis subphenotypes with different natural histories following admission
433 to the ICU. Our results suggest that these subphenotypes represent a differential host
434 pathogen response in the setting of current standard of care therapy. Understanding
435 differential trajectory has implications for the design and predictive enrichment of therapeutic
436 clinical trials.³⁸ Further understanding of the underlying biology of subphenotypes may
437 reveal insights into sepsis pathophysiology and improve the personalization of sepsis
438 management.

439

440 **Abbreviations:** ICU: Intensive Care Unit; DTW: Dynamic Time Warping; HAC: Hierarchical
441 Agglomerative Clustering; SOFA: Sequential Organ Failure Assessment; GBTM: Group-Based
442 Trajectory Modeling; LCA: Latent Class Analysis; EHR: Electronic Health Record; MIMIC-III:
443 Medical Information Mart for Intensive Care III database; BIDMC: Beth Israel Deaconess Medical
444 Center; NMEDW: Northwestern Medicine Enterprise Data Warehouse; CEDAR: Critical care
445 Database for Advanced Research; NYP/WCMC: NewYork-Presbyterian/Weill Cornell Medical
446 Center; CNS: Central Nervous System; LOCF: Last Observation Carried Forward; NOCB: Next
447 Observation Carried Backward; SHAP: Shapley Additive Explanations; MICU: Medical Intensive
448 Care Unit; SD: Standard Deviation; WBC: White Blood Cell Count; RDW: Red Blood Cell
449 Distribution Width; CRP: C-reactive protein; CI: Confidence Interval; AST: Aspartate
450 Aminotransferase.

451

452

453 **Acknowledgements**

454 The work of ZX, CZ, HZ and FW are supported by NSF 1750326, NIH RF1AG072449 and
455 NIH R01MH124740. The work of ES is supported by NHLBI K23HL151876. The work of
456 CM and YL are supported in part by NIH 1R01LM013337 and U01TR003528.

457

458 **Author contributors:** ES and FW for conceptualization, investigation, writing, reviewing
459 and editing of the manuscript. ZX for data analysis, drafting, editing and reviewing

460 manuscript. CM for data analysis, editing and reviewing manuscript. CS, HZ, IS, LT and DP
461 for discussion, commenting and editing the manuscript. YL, CM, ZX, FW, and ES verified
462 the data. YL and CM had access to the raw data from the NMEDW. FW, ES, and ZX had
463 access to the raw data from the CEDAR, eICU, and MIMIC-III.

464

465 **Funding**

466 The research fundings are from NSF and NIH.

467

468 **Availability of data and materials**

469 The deidentified data from development cohort (MIMIC-III) and data from validation cohort
470 (eICU) can be obtained after approval of proposal with a signed data access agreement by
471 checking physionet (The Research Resource for Complex Physiologic Signals,
472 <https://physionet.org/>). For validation cohorts (NMEDW and CEDAR), data access are not
473 covered by our data transfer agreements. All source codes in this study are available at
474 https://github.com/xuzhenxing2019/sepsis_subphenotype. Our implementation is based on
475 Python 3.7 and R 3.6. More specifically, clustering models were implemented by using Python
476 packages ‘scikit-learn 0.23.2’ (<https://scikit-learn.org/stable/>) and ‘scipy 1.5.3’
477 (<https://www.scipy.org>). The implementation of SHAP is based on ‘SHAP 0.35.0’
478 (<https://shap.readthedocs.io/en/latest/>). R package ‘NbClust’ ([https://cran.r-
479 project.org/web/packages/NbClust/NbClust.pdf](https://cran.r-project.org/web/packages/NbClust/NbClust.pdf)) was used to determine the optimal number of
480 clusters in agglomerative hierarchical clustering. Chord diagrams were created using R
481 package ‘circlize’ (<https://cran.r-project.org/web/packages/circlize/index.html>). Statistical
482 tests and survival analyses were performed based on R.

483

484 **Declarations**

485

486 **Ethics approval and consent to participate**

487 Consent obtained for use of MIMIC-III, eICU, NMEDW and CEDAR databases.

488

489 **Consent for publication**

490 Not applicable

491

492 **Competing interests**

493 ES received the consulting fees in terms of Axle Informatics (NIAID COVID19 Vaccine Subject Matter
494 Expert Program) and payment in terms of Department of Defense (Peer Reviewed Medical Research
495 Program). All other authors declare no competing interests.

496

497 **Author details:** ¹Division of Health Informatics, Department of Population Health Sciences, Weill
498 Cornell Medicine, New York, NY, USA; ²Division of Health and Biomedical Informatics, Department
499 of Preventive Medicine Center for Health Information Partnerships, Feinberg School of Medicine,
500 Northwestern University, Chicago, IL, USA; ³Department of Health Service Administration and Policy,
501 College of Public Health, Temple University, Philadelphia, PA, USA; ⁴Division of Pulmonary and
502 Critical Care Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY,
503 USA; ⁵Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA.

504

505

506

507

508

509

510

511 References

- 512 1. Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying
513 novel sepsis subphenotypes using temperature trajectories. *American journal of respiratory*
514 *and critical care medicine* 2019; **200**(3): 327-35.
- 515 2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
516 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; **315**(8): 801-10.
- 517 3. Rhee C, Dantes R, Epstein L, et al. Incidence and Trends of Sepsis in US Hospitals
518 Using Clinical vs Claims Data, 2009-2014. *JAMA* 2017; **318**(13): 1241-9.
- 519 4. Mullard A. Drug withdrawal sends critical care specialists back to basics. *Lancet*
520 2011; **378**(9805): 1769-.
- 521 5. Seymour CW, Kennedy JN, Wang S, et al. Derivation, Validation, and Potential
522 Treatment Implications of Novel Clinical Phenotypes for Sepsis. *JAMA* 2019; **321**(20): 2003-
523 17.
- 524 6. Abraham E. Moving Forward With Refinement of Definitions for Sepsis. *Crit Care*
525 *Med* 2021; **49**(5): 861-3.
- 526 7. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. *Lancet Infect Dis*
527 2012; **12**(7): 503-5.
- 528 8. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research.
529 *Lancet Infect Dis* 2015; **15**(5): 581-614.
- 530 9. DeMerle KM, Angus DC, Baillie JK, et al. Sepsis Subclasses: A Framework for
531 Development and Interpretation. *Crit Care Med* 2021; **49**(5): 748-59.
- 532 10. Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within
533 sepsis-associated multiple organ dysfunction syndrome. *Intens Care Med* 2015; **41**(5): 814-
534 22.
- 535 11. Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with
536 sepsis according to blood genomic endotype: a prospective cohort study. *Lancet Resp Med*
537 2017; **5**(10): 816-26.
- 538 12. Sweeney TE, Azad TD, Donato M, et al. Unsupervised Analysis of Transcriptomics in
539 Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters. *Critical Care*
540 *Medicine* 2018; **46**(6): 915-25.
- 541 13. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA
542 score to predict outcome in critically ill patients. *Jama-J Am Med Assoc* 2001; **286**(14): 1754-
543 8.
- 544 14. Sakr Y, Lobo SM, Moreno RP, et al. Patterns and early evolution of organ failure in
545 the intensive care unit and their relation to outcome. *Critical care* 2012; **16**(6): 1-9.
- 546 15. Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and
547 validation of novel phenotypes of multiple organ dysfunction syndrome in critically ill children.
548 *JAMA network open* 2020; **3**(8): e209271-e.
- 549 16. Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure
550 assessment) score to describe organ dysfunction/failure. *Intens Care Med* 1996; **22**(7): 707-
551 10.
- 552 17. Berndt DJ, Clifford J. Using dynamic time warping to find patterns in time series.
553 KDD workshop; 1994: Seattle, WA, USA.; 1994. p. 359-70.
- 554 18. Jain AK, Murty MN, Flynn PJ. Data clustering: a review. *ACM computing surveys*
555 *(CSUR)* 1999; **31**(3): 264-323.
- 556 19. Johnson AEW, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care
557 database. *Sci Data* 2016; **3**.
- 558 20. Starren JB, Winter AQ, Lloyd-Jones DM. Enabling a learning health system through a
559 unified enterprise data warehouse: the experience of the northwestern university clinical and
560 translational sciences (NUCATS) institute. *Clin Transl Sci* 2015; **8**(4): 269-71.
- 561 21. Pollard TJ, Johnson AE, Raffa JD, Celi LA, Mark RG, Badawi O. The eICU
562 Collaborative Research Database, a freely available multi-center database for critical care
563 research. *Sci Data* 2018; **5**(1): 1-13.
- 564 22. Schenck EJ, Hoffman KL, Cusick M, Kabariti J, Sholle ET, Campion Jr TR. Critical
565 carE Database for Advanced Research (CEDAR): An automated method to support

- 566 intensive care units with electronic health record data. *Journal of Biomedical Informatics*
567 2021; **118**: 103789.
- 568 23. Moritz S, Bartz-Beielstein T. imputeTS: time series missing value imputation in R. *R J*
569 2017; **9**(1): 207.
- 570 24. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. *Annual*
571 *review of clinical psychology* 2010; **6**: 109-38.
- 572 25. Molnar C. Interpretable machine learning: Lulu. com; 2020.
- 573 26. Quan HD, Sundararajan V, Halfon P, et al. Coding algorithms for defining
574 comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005; **43**(11): 1130-9.
- 575 27. Schenck EJ, Oromendia C, Torres LK, Berlin DA, Choi AMK, Siempos II. Rapidly
576 Improving ARDS in Therapeutic Randomized Controlled Trials. *Chest* 2019; **155**(3): 474-82.
- 577 28. Woźnica EA, Ingot M, Woźnica RK, Łysenko LJAic, University emooWM. Liver
578 dysfunction in sepsis. 2018; **27**(4): 547-51.
- 579 29. Gaudry S, Hajage D, Benichou N, et al. Delayed versus early initiation of renal
580 replacement therapy for severe acute kidney injury: a systematic review and individual
581 patient data meta -analysis of randomised clinical trials. *Lancet* 2020; **395**(10235): 1506-15.
- 582 30. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development,
583 utility and challenges of accurate assessment in clinical trials. *Critical Care* 2019; **23**(1): 1-9.
- 584 31. Abrams D, Montesi SB, Moore SKL, et al. Powering bias and clinically important
585 treatment effects in randomized trials of critical illness*. 2020; **48**(12): 1710-9.
- 586 32. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis
587 and septic shock. *Nature Reviews Disease Primers* 2016; **2**(1): 16045.
- 588 33. Ma KC, Schenck EJ, Siempos II, et al. Circulating RIPK3 levels are associated with
589 mortality and organ failure during critical illness. 2018; **3**(13).
- 590 34. Linkermann A. Death and fire—the concept of necroinflammation. *Cell Death &*
591 *Differentiation* 2019; **26**(1): 1-3.
- 592 35. Schenck EJ, Ma KC, Price DR, et al. Circulating cell death biomarker TRAIL is
593 associated with increased organ dysfunction in sepsis. 2019; **4**(9).
- 594 36. Mira JC, Gentile LF, Mathias BJ, et al. Sepsis Pathophysiology, Chronic Critical
595 Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. 2017;
596 **45**(2): 253-62.
- 597 37. Cao C, Yu M, Chai Y. Pathological alteration and therapeutic implications of sepsis-
598 induced immune cell apoptosis. *Cell Death & Disease* 2019; **10**(10): 782.
- 599 38. Granholm A, Alhazzani W, Derde LPG, et al. Randomised clinical trials in critical
600 care: past, present and future. *Intens Care Med* 2021.

601
602
603
604
605
606

607 **Figure Title and Legend:**

608 **Figure 1. Workflow of study.** (A) The MIMIC-III dataset was used as development cohort
609 and NMEDW, eICU, and CEDAR datasets were used as validation cohorts. Electronic health
610 records including lab tests, vital signs, and medication were extracted to compute the SOFA
611 score every 6 hours during 72 hours after admission to ICU. (B) Each patient was represented
612 as a 72-hour SOFA score trajectory. Dynamic Time Warping (DTW) was used to compute
613 heterogeneous SOFA trajectory similarities and HAC was applied to identify subphenotypes
614 based on trajectory similarities. (C) To re-derive subphenotypes in three validation cohorts and
615 consider sensitivity analysis to clustering method, specifically, use another method (Group-
616 Based Trajectory Modeling, GBTM) to generate subphenotypes. Statistical analysis were
617 performed among subphenotypes in terms of demographic factors, lab tests and vital signs. (D)
618 The predictive model of subphenotypes at successive time points (hours 6, 24, 36, 48, 60) after
619 ICU admission was constructed based on a random forest classifier by using patients' clinical
620 data including lab tests, vital signs, and SOFA subscores.

621

622 **Figure 2. Sequential Organ Failure Assessment (SOFA) trajectories of the identified**
623 **subphenotypes in development and three validation cohorts.** DI: Delayed Improving; RI:
624 Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening.

625

626 **Figure 3. The prevalence of each subphenotype in development (MIMIC-III) and other**
627 **three validation cohorts (NMEDW, eICU, CEDAR).** DI: Delayed Improving; RI: Rapidly
628 Improving; DW: Delayed Worsening; RW: Rapidly Worsening.

629

630 **Figure 4. Survival analysis in terms of the identified subphenotypes in development and**
631 **three validation cohorts.** DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed
632 Worsening; RW: Rapidly Worsening. The (A), (B), (C), and (D) show the survival analysis
633 results in development and three validation cohorts, respectively.

634

635 **Figure 5. Chord diagrams showing abnormal variables by subphenotype in development**
636 **cohort.** a: abnormal biomarkers vs. all subphenotypes; I: abnormal biomarkers vs. DI; II:
637 abnormal biomarkers vs. RI; III: abnormal biomarkers vs. DW; IV: abnormal biomarkers vs.
638 RW; b: abnormal subscores vs. all subphenotypes; V: abnormal subscores vs. DI; VI: abnormal
639 subscores vs. RI; VII: abnormal subscores vs. DW; VIII: abnormal subscores vs. RW. DI:
640 Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly
641 Worsening.

642

643 **Figure 6. SHAP value-based predictor contribution to the subphenotype prediction of**
644 **the predictive model in development cohort.** Features' importance is ranked based on
645 SHAP values. In this figure, each point represented a single observation. The horizontal
646 location showed whether the effect of that value was associated with a positive (a SHAP
647 value greater than 0) or negative (a SHAP value less than 0) impact on prediction. Color
648 showed whether the original value of that variable was high (in red) or low (in blue) for that
649 observation. For example, in RW, a low Platelets value had a positive impact on the RW
650 subphenotype prediction; the "low" came from the blue color, and the "positive" impact was
651 shown on the horizontal axis. DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed
652 Worsening; RW: Rapidly Worsening.

653

654

655 **Table**

656 **Table 1. Patient Characteristics among Subphenotypes in the Development Cohort**








Figure 1. Workflow of study. (A) The MIMIC-III dataset was used as development cohort and NMEDW, eICU, and CEDAR datasets were used as validation cohorts. Electronic health records including lab tests, vital signs, and medication were extracted to compute the SOFA score every 6 hours during 72 hours after admission to ICU. (B) Each patient was represented as a 72-hour SOFA score trajectory. Dynamic Time Warping (DTW) was used to compute heterogeneous SOFA trajectory similarities and HAC was applied to identify subphenotypes based on trajectory similarities. (C) To re-derive subphenotypes in three validation cohorts and consider sensitivity analysis to clustering method, specifically, use another method (Group-Based Trajectory Modeling, GBTM) to generate subphenotypes. Statistical analysis were performed among subphenotypes in terms of demographic factors, lab tests and vital signs. (D) The predictive model of subphenotypes at successive time points (hours 6, 24, 36, 48, 60) after ICU admission was constructed based on a random forest classifier by using patients' clinical data including lab tests, vital signs, and SOFA subscores.


Development Cohort



Validation Cohort (NMEDW)



Validation Cohort (eICU)



Validation Cohort (CEDAR)




Figure 2. Sequential Organ Failure Assessment (SOFA) trajectories of the identified subphenotypes in development and three validation cohorts. DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening.






Figure 3. The prevalence of each subphenotype in development (MIMIC-III) and other three validation cohorts (NMEDW, eICU, CEDAR). DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening.

Subphenotypes DI RI DW RW


A
Development Cohort



B
Validation Cohort (NMEDW)



C
Validation Cohort (eICU)



D
Validation Cohort (CEDAR)




Figure 4. Survival analysis in terms of the identified subphenotypes in development and three validation cohorts. DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening. The (A), (B), (C), and (D) show the survival analysis results in development and three validation cohorts, respectively.




Figure 5. Chord diagrams showing abnormal variables by subphenotype in development cohort. a: abnormal biomarkers vs. all subphenotypes; I: abnormal biomarkers vs. DI; II: abnormal biomarkers vs. RI; III: abnormal biomarkers vs. DW; IV: abnormal biomarkers vs. RW; b: abnormal subscores vs. all subphenotypes; V: abnormal subscores vs. DI; VI: abnormal subscores vs. RI; VII: abnormal subscores vs. DW; VIII: abnormal subscores vs. RW. DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening.





DI**RI****DW****RW**High
Feature value
LowHigh
Feature value
Low

Figure 6. SHAP value-based predictor contribution to the subphenotype prediction of the predictive model in development cohort. Features' importance is ranked based on SHAP values. In this figure, each point represented a single observation. The horizontal location showed whether the effect of that value was associated with a positive (a SHAP value greater than 0) or negative (a SHAP value less than 0) impact on prediction. Color showed whether the original value of that variable was high (in red) or low (in blue) for that observation. For example, in RW, a low Platelets value had a positive impact on the RW subphenotype prediction; the "low" came from the blue color, and the "positive" impact was shown on the horizontal axis. DI: Delayed Improving; RI: Rapidly Improving; DW: Delayed Worsening; RW: Rapidly Worsening.